Study of the Effect of Intralipid Infusion during Pregnancy as an Additive Treatment for Reducing Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome
Aim: To evaluate the safety and efficacy of intralipid
infusion in addition to other lines of treatment in reduction of complications
caused by antiphospholipid antibody syndrome. Methods: This study was
held in the period from June 1, 2016, to December 1, 2019. This study was
conducted in the Department of Obstetrics and Gynecology, Tanta University on
patients attending the antenatal care clinic and also on patients attending the
researcher’s private clinics for antenatal care, 105 patients were enrolled after
application of strict inclusion and exclusion criteria. They were randomized into
2 groups. In group A (study group 1) the patients received in addition to the
conventional basic treatment of APS, intralipid 20% (Frezenius, Clayton, NC,
USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline IV and to be
repeated every 2 weeks. In group B (control group 2) the patients received the
conventional basic treatment of APS. The outcome measures were the incidence of
pregnancy complications of APS namely fetal loss, premature delivery, IUGR and
preeclampsia. Results: 49 patients were enrolled in the study group, and
48 patients were enrolled in the control group, after exclusion of the skipped
cases. The demographic data and the gestational age at the beginning of the
study show insignificant differences. There were insignificant differences as
regard the gestational age at which the pregnancy was terminated and fetal
birth weight in patients with positive ACL test, positive LA test and positive
B2 however the mean gestational age at which pregnancy was terminated was
higher in study group. Also, there was insignificant difference as regards no
of patients who complicated with abortion or who completed to full term. But
had significant decrease number of case who complicated with preeclampsia (8,
21 patients in study and control group respectively). Conclusion: Intralipid
infusion is a promising treatment option for control and prevention of problems
caused by antiphospholipid antibody syndrome.
References
[1]
Sammaritano, L.R. (2019) Antiphospholipid Syndrome. Best Practice & Research Clinical Rheumatology, 34, Article ID: 101463.
https://doi.org/10.1016/j.berh.2019.101463
[2]
Olayemi, E.E. and Bazuaye, G.N. (2007) Presence of Lupus Anticoagulant in an Asymptomatic Nigerian. African Health Sciences, 7, 182-184.
[3]
Oku, K., Amengual, O. and Atsumi, T. (2012) Pathophysiology of Thrombosis and Pregnancy Morbidity in the Antiphospholipid Syndrome. European Journal of Clinical Investigation, 42, 1126-1135.
https://doi.org/10.1111/j.1365-2362.2012.02697.x
[4]
Meroni, P.L., Orietta Borghi, M., Raschi, E. and Tedesco, F. (2011) Pathogenesis of Antiphospholipid Syndrome: Understanding the Antibodies. Nature Reviews Rheumatology, 7, 330-339. https://doi.org/10.1038/nrrheum.2011.52
[5]
Wijetilleka, S., Scoble, T. and Khamashta, M. (2012) Novel Insights into Pathogenesis, Diagnosis and Treatment of Antiphospholipid Syndrome. Current Opinion in Rheumatology, 24, 473-481. https://doi.org/10.1097/BOR.0b013e328354ae8c
[6]
Levine, J.S., Branch, D.W. and Rauch, J. (2002) The Antiphospholipid Syndrome. New England Journal of Medicine, 346, 752-763.
https://doi.org/10.1056/NEJMra002974
[7]
Blétry, O. and Piette, A.M. (1997) Recurrent Fetal Loss and Antiphospholipid Antibodies: Clinical and Therapeutic Aspects. Infectious Diseases in Obstetrics and Gynecology, 5, Article ID: 480963. https://doi.org/10.1155/S1064744997000288
[8]
Branch, D.W., Silver, R.M. and Porter, T.F. (2010) Obstetric Antiphospholipid Syndrome: Current Uncertainties Should Guide Our Way. Lupus, 19, 446-452.
https://doi.org/10.1177%2F0961203310361490
[9]
Lima, F., Khamashta, M.A., Buchanan, N.M., Kerslake, S., Hunt, B.J. and Hughes, G.R. (1996) A Study of Sixty Pregnancies in Patients with the Antiphospholipid Syndrome. Clinical and Experimental Rheumatology, 14, 131-136.
[10]
Yamada, H., Atsumi, T., Kobashi, G., Ota, C., Kato, E.H., Tsuruga, N., et al. (2009) Antiphospholipid Antibodies Increase the Risk of Pregnancy-Induced Hypertension and Adverse Pregnancy Outcomes. Journal of Reproductive Immunology, 79, 188-195. https://doi.org/10.1016/j.jri.2008.11.001
[11]
Caruso, A., De Carolis, S., Ferrazzani, S., Valesini, G., Caforio, L. and Mancuso, S. (1993) Pregnancy Outcome in Relation to Uterine Artery Flow Velocity Waveforms and Clinical Characteristics in Women with Antiphospholipid Syndrome. Obstetrics & Gynecology, 82, 970-977.
[12]
Dadhwal, V., Sharma, A.K., Deka, D., Gupta, B. and Mittal, S. (2011) The Obstetric Outcome Following Treatment in a Cohort of Patients with Antiphospholipid Antibody Syndrome in a Tertiary Care Center. Journal of Postgraduate Medicine, 57, 16-19. https://doi.org/10.4103/0022-3859.74285
[13]
Bramham, K., Hunt, B.J., Germain, S., Calatayud, I., Khamashta, M., Bewley, S., et al. (2010) Pregnancy Outcome in Different Clinical Phenotypes of Antiphospholipid Syndrome. Lupus, 19, 58-64. https://doi.org/10.1177%2F0961203309347794
[14]
Espinosa, G. and Cervera, R. (2015) Current Treatment of Antiphospholipid Syndrome: Lights and Shadows. Nature Reviews Rheumatology, 11, 586-596.
https://doi.org/10.1038/nrrheum.2015.88
[15]
Ruffatti, A., Tonello, M., Hoxha, A., Sciascia, S., Cuadrado, M.J., Latino, J.O., et al. (2018) Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Journal of Thrombosis and Haemostasis, 118, 639-646.
https://doi.org/10.1055/s-0038-1632388
[16]
Bramham, K., Thomas, M., Nelson-Piercy, C., Khamashta, M. and Hunt, B.J. (2011) First-Trimester Low-Dose Prednisolone in Refractory Antiphospholipid Antibody-Related Pregnancy Loss. Blood, 117, 6948-6951.
https://doi.org/10.1182/blood-2011-02-339234
[17]
Lefkou, E., Mamopoulos, A., Dagklis, T., Vosnakis, C., Rousso, D. and Girardi, G. (2016) Pravastatin Improves Pregnancy Outcomes in Obstetric Antiphospholipid Syndrome Refractory to Antithrombotic Therapy. Journal of Clinical Investigation, 126, 2933-2940. https://doi.org/10.1172/JCI86957
[18]
Ruffatti, A., Salvan, E., Del Ross, T., Gerosa, M., Andreoli, L., Maina, A., et al. (2014) Treatment Strategies and Pregnancy Outcomes in Antiphospholipid Syndrome Patients with Thrombosis and Triple Antiphospholipid Positivity. A European Multicentre Retrospective Study. Journal of Thrombosis and Haemostasis, 112, 727-735. https://doi.org/10.1160/TH14-03-0191
[19]
David, A.C. (1994) Intralipid as Treatment for Recurrent Unexplained Abortion? American Journal of Reproductive Immunology, 32, 290-293.
https://doi.org/10.1111/j.1600-0897.1994.tb01128.x
[20]
Dina, M.R., Yomna, A., Mohamed, Sh., Sherine, H. and Waleed, E. (2016) Intralipid Supplementation in Women with Recurrent Spontaneous Abortion and Elevated Levels of Natural Killer Cells. International Journal of Gynecology & Obstetrics, 135, 324-327. https://doi.org/10.1016/j.ijgo.2016.06.026
[21]
Anne, E.M., Sue, J., Louis, F., Meike, L.U. and Jennifer, E. (2018) Evaluating the Utility of Intralipid Infusion to Improve Live Birth Rates in Patients with Recurrent Pregnancy Loss or Recurrent Implantation Failure. Journal of Human Reproductive Sciences, 11, 261-268. https://doi.org/10.4103/jhrs.JHRS_28_18
[22]
Léo, P., Kamilla, K., Yasmine Ben, K., Jonathan, C., Ludovic, S., Marie, B., et al. (2020) Intralipid Therapy for Unexplained Recurrent Miscarriage and Implantation Failure: Case-Series and Literature Review. European Journal of Obstetrics & Gynecology and Reproductive Biology, 252, 100-104.
https://doi.org/10.1016/j.ejogrb.2020.06.017
[23]
Chiara, A., Montserrat, D., Wael, S., Paul, S. and Srividya, S. (2018) The Role of Immunotherapy in in Vitro Fertilization and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Fertility and Sterility, 110, 1089-1100.
https://doi.org/10.1016/j.fertnstert.2018.07.004
[24]
Malgorzata, J., Monika, S., Monika, K. and Andrzej, G. (2016) Successful Pregnancy after Intralipid addition to Sildenafil and Enoxaparin in Woman with History of Recurrent Pregnancy Loss (RPL). Neuro Endocrinology Letters, 37, 473-477.
[25]
Carolyn, B. and Brian, A. (2012) Does Immunotherapy for Treatment of Reproductive Failure Enhance Live Births? American Journal of Reproductive Immunology, 67, 296-304. https://doi.org/10.1111/j.1600-0897.2012.01111.x
[26]
Jawharah, A., Sahar, L. and Dania, A. (2018) The Effect of Fat Emulsion Intralipid 20% in Reproductive Outcome for Patients with Multiple Implantation Failure. International Journal of Women’s Health and Reproduction Sciences, 6, 144-149.
https://doi.org/10.15296/ijwhr.2018.24
